EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
NEW YORK, April 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
Summary
The urogenital tract, specifically the vagina, urethra, bladder, trigone of the bladder, and pelvic floor muscles, contains estrogen receptors. Estrogen is needed for the health of these tissues and structures, a lack of which causes them to undergo atrophy (Castelo-Branco and Rostro, 2007; Nappi and Kokot-Kierepa, 2012). During the menopause transition and postmenopausal periods, women can experience a number of symptoms primarily due to estrogen depletion that include vasomotor and urogenital symptoms. Although vasomotor symptoms typically resolve over time, urogenital symptoms remain a persistent consequence of estrogen depletion (Winneker and Harris, 2011). Postmenopausal vaginal atrophy (PVA) is the term used to describe the group of urogenital symptoms that arise due to estrogen depletion and is also known as urogenital atrophy, vulvovaginal atrophy, and atrophic vaginitis (Mac Bride et al., 2010; Willhite and O'Connell, 2001). Approximately 10%–50% of postmenopausal women experience symptoms of vaginal atrophy, but only about 25% of them seek medical treatment (NAMS, 2007; Nappi and Kokot-Kierepa, 2012).
Cultural and social attitudes toward sexuality and aging are the primary determinants of the extent to which women report symptoms associated with PVA; therefore, the amount of PVA epidemiology data available in a given country varies considerably (Barlow et al., 1997). Today, women are living longer and spend approximately one third of their lives in the postmenopausal state. For this reason, there is evidence that in some regions, such as North America, attitudes towards the menopause transition are changing, and women are becoming more vocal about their menopause experience (Wright, 1998). Any changes in cultural and social norms that decrease the stigma surrounding menopause will likely lead to an increase in the diagnosed prevalence of PVA over time. The increase could exceed the projections of PVA prevalence found in this analysis.
Scope
- The Postmenopausal Vaginal Atrophy EpiCast Report provides an overview of the risk factors and global trends of postmenopausal vaginal atrophy in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan).
- It includes a 10-year epidemiology forecast of PVA prevalent cases segmented by age (in five-year increments beginning at 50 years and ending at 79 years) and severity (mild, moderate, and severe) in the 7MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global postmenopausal vaginal atrophy market.
- Quantify patient populations in the global postmenopausal vaginal atrophy market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and severity levels that present the best opportunities for postmenopausal vaginal atrophy therapeutics in each of the markets covered.
- Identify the percentage of postmenopausal vaginal atrophy cases that are mild, moderate, and severe
Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Risk Factors and Comorbidities 7
3.1.1 Sexual inactivity increases symptoms of postmenopausal vaginal atrophy 8
3.1.2 Smoking causes early menopause and exacerbates atrophic vaginal changes 8
3.1.3 PVA prevalence is higher in women who have undergone cancer treatment 8
3.2 Global Trends 9
3.3 Forecast Methodology 10
3.3.1 Sources Used 12
3.3.2 Forecast Assumptions and Methods 13
3.3.3 Sources Not Used 15
3.4 Epidemiology Forecast of Postmenopausal Vaginal Atrophy 16
3.4.1 Prevalent Cases of Postmenopausal Vaginal Atrophy 16
3.4.2 Age-Specific Prevalent Cases of Postmenopausal Vaginal Atrophy 17
3.4.3 Postmenopausal Vaginal Atrophy by Severity 19
3.5 Discussion 21
3.5.1 Conclusions on Epidemiological Trends 21
3.5.2 Limitations of Analysis 22
3.5.3 Strengths of Analysis 23
4 Appendix 24
4.1 Bibliography 24
4.2 About the Authors 27
4.2.1 Epidemiologists 27
4.2.2 Reviewers 27
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 28
4.2.4 Global Head of Healthcare 29
4.3 About GlobalData 29
4.4 About EpiCast 29
4.5 Contact Us 30
4.6 Disclaimer 30
List of Tables
Table 1: Sources of Prevalence Data Used in the Epidemiology Forecast 11
Table 2: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, N, Select Years, 2012–2022 16
Table 3: 7MM, Calculated Total Prevalence of Postmenopausal Vaginal Atrophy, By Age, %, 2012–2022 18
Table 4: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Age, N, 2012 18
Table 5: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Severity, N (Row %), 2012 20
List of Figures
Figure 1: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, N, Select Years, 2012–2022 17
Figure 2: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Age, N, 2012 19
Figure 3: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Severity, N (%), 2012 20
To order this report:
General_Medicine_and_Specialty_Medicine Industry: EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article